Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California. Show more
Location: 11025 North Torrey Pines Road, La Jolla, La Jolla, CA, 92037, United States | Website: https://inhibrx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
402.7M
52 Wk Range
$10.80 - $28.49
Previous Close
$27.80
Open
$27.91
Volume
72,036
Day Range
$27.01 - $28.25
Enterprise Value
322.9M
Cash
186.6M
Avg Qtr Burn
-34.96M
Insider Ownership
27.17%
Institutional Own.
65.61%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INBRX-106 (OX40 agonist) + Keytruda Details Head and neck squamous cell carcinoma Suspected Mover™ Susp. Mover™ | Phase 2/3 Data readout | |
Phase 2 Data readout | ||
INBRX-106 Details Non-small cell lung cancer | Phase 1/2 Data readout | |
Ozekibart (INBRX-109) + FOLFIRI Details Metastatic colorectal cancer | Phase 1 Data readout | |
Ozekibart (INBRX-109) (DR5 agonist) Details Relapsed/refractory Ewing sarcoma | Phase 1 Data readout | |
INBRX-105 (PDL1 X 4-1BB tetravalent conditional agonist) +/- Keytruda Details Cancer, Solid tumor/s | Failed Discontinued |